Percheron Therapeutics (PER) - Recruitment Accelerated - Data Readout Likely Q1 CY25
PER announced that 34 out of a total target of 45 patients have commenced treatment in its randomised Phase IIb trial of lead drug ATL1102
175 Views
Antisense - Looking Forward to Key DMD Efficacy Readout in 2024
The Phase IIb trial will primarily serve as a signal finding study to determine whether the drug has sufficient efficacy to be an effective...
235 Views
Antisense Therapeutics - Breaking the mould in DMD treatment
Antisense Therapeutics is an Australian biotechnology company developing antisense oligonucleotide (ASO) therapies for the treatment of rare...
665 Views
Taxing Times For Australia
The Government's release of Re:think, its tax discussion paper, is a welcome development, designed to kick-start the conversation with the...
5.7k Views
No more insights